The positive interim data, expanded addressable population, and the upcoming Q4 2026 catalyst (topline data + Type-B meeting) position GX-03 as a potentially best-in-class topical therapy for atopic dermatitis. Traders should monitor enrollment progress and any competitive pipeline updates, with Q4 2026 as the next major value-inflection point.
Price Chart
Executive Summary
Turn Therapeutics announced the completion of a comprehensive interim analysis of its adaptive Phase 2 trial for GX-03 in atopic dermatitis, revealing clinically meaningful efficacy across a broader spectrum of disease severity. This led to an expanded Stage 2 design enrolling ~120-135 patients across the full EASI baseline spectrum (≥1.1) with a Hochberg multiple-testing procedure across four endpoints. Topline results are expected in Q4 2026 with a Type-B meeting with the FDA also expected that quarter.
Key Facts
- Interim analysis on first 50 subjects completed; Stage 2 design finalized for ~120-135 patients.
- Stage 2 will use FDA-recognized Hochberg multiple testing procedure across four endpoints: Week 4 vIGA-AD Success, Week 4 EASI-75, Week 8 EASI-90, Week 8 EASI-100.
- Representative subgroup (EASI ≥1.1, PP-NRS ≥7): GX-03 vs vehicle showed treatment differences of +53.2% (Week 4 vIGA-AD), +44.2% (Week 4 EASI-75), +37.1% (Week 8 EASI-90), +37.9% (Week 8 EASI-100).
- No treatment-related serious adverse events or discontinuations observed; safety profile favorable.
- Company remains capitalized through Q3 2027; enrollment ongoing with Q4 2026 topline expected.
- Q4 2026 Type-B meeting with FDA also anticipated.
Financial Impact
No financial figures reported; company is clinical-stage with no revenue.
Risk Factors
- Interim analysis data are from small subgroups (n=13-14 GX-03, n=12-18 vehicle) and may not replicate in the full Stage 2 population of ~120-135 patients.
- No head-to-head data vs approved topical AD therapies; cross-trial comparisons are illustrative only.
- Future Phase 3 initiation and regulatory approval depend on successful Stage 2 results and capital availability beyond Q3 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-075757 |
| Document: ea029706101ex99-1.htm | 0001213900-26-075757 |
| Document: ea0297061-8k_turn.htm | 0001213900-26-075757 |
| Document: 0001213900-26-075757-index-headers.html | 0001213900-26-075757 |
| Document: 0001213900-26-075757-index.html | 0001213900-26-075757 |
| Document: 0001213900-26-075757.txt | 0001213900-26-075757 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $10.47 | awaiting T+60 | — | $10.31 (−1.48%) |
Oct 6, 2026 20d ago | 8-K | $12.10 | awaiting T+60 | — | $10.31 (−14.75%) |
Sep 10, 2026 6w ago | 8-K | $13.38 | awaiting T+60 | — | $10.31 (−22.91%) |
Sep 9, 2026 6w ago | 8-K | $13.75 | awaiting T+60 | — | $10.31 (−24.98%) |
Aug 18, 2026 10w ago | 8-K | $9.99 | awaiting T+60 | — | $10.31 (+3.25%) |
Jul 7, 2026 16w ago | 8-K | $9.71 $14.39 | ▲ +48.20% | ▲ +46.20% | $10.31 (+6.23%) |
Jun 3, 2026 20w ago | 8-K | $6.02 $10.11 | ▲ +67.94% | ▲ +65.44% | $10.31 (+71.35%) |
Jun 1, 2026 21w ago | 8-K | $6.33 $9.73 | ▲ +53.71% | ▲ +52.48% | $10.31 (+62.95%) |
May 27, 2026 21w ago | 8-K | $5.29 $9.54 | ▲ +80.34% | ▲ +78.46% | $10.31 (+94.99%) |
May 19, 2026 23w ago | 8-K | $4.55 $9.86 | ▲ +116.70% | ▲ +110.41% | $10.31 (+126.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers